Literature DB >> 3323251

Use of antimesothelial cell antibody and computer assisted quantitative analysis for distinguishing between reactive and neoplastic serosal tissues.

A Donna1, P G Betta, F Robutti.   

Abstract

Nine malignant mesotheliomas and 12 specimens of benign reactive mesothelial hyperplasia were examined using a specific antimesothelial cell antibody. Immunostaining intensity was subsequently estimated by means of image analysis. The mean and standard deviation of integrated optical density in the malignant mesotheliomas differed significantly from those in the mesothelial hyperplasias. In all mesotheliomas but one the integrated optical density was greater than in reactive mesothelial hyperplasia. No significant difference in optical density was observed between the two groups; the standard deviation was significantly higher in the reactive lesions. This technique may be adopted to complement the traditional morphological assessment of primary lesions of the serosal cavities.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323251      PMCID: PMC1141278          DOI: 10.1136/jcp.40.12.1428

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

1.  A new marker for human cancer cells. 3. Immunocytochemical detection of malignant cells in serous fluids with the Ca1 antibody.

Authors:  J C Woods; A I Spriggs; H Harris; J O McGee
Journal:  Lancet       Date:  1982-09-04       Impact factor: 79.321

2.  Ca2 and Ca3. New monoclonal antibodies evaluated as tumor markers in serous effusions.

Authors:  M E Bramwell; A K Ghosh; W D Smith; G Wiseman; A I Spriggs; H Harris
Journal:  Cancer       Date:  1985-07-01       Impact factor: 6.860

3.  Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies.

Authors:  A K Ghosh; A I Spriggs; J Taylor-Papadimitriou; D Y Mason
Journal:  J Clin Pathol       Date:  1983-10       Impact factor: 3.411

4.  Indirect immunoalkaline phosphatase staining of cytologic smears of serous effusions for tumor marker studies.

Authors:  A To; D P Dearnaley; M G Ormerod; G Canti; D V Coleman
Journal:  Acta Cytol       Date:  1983 Mar-Apr       Impact factor: 2.319

5.  Interpretation of pleural biopsy specimens and aspirates with the immunoperoxidase technique.

Authors:  A Herbert; P J Gallagher
Journal:  Thorax       Date:  1982-11       Impact factor: 9.139

6.  Quantitative and qualitative differences between benign and malignant mesothelial cells in pleural fluid.

Authors:  W S Kwee; R W Veldhuizen; C A Alons; F Morawetz; M E Boon
Journal:  Acta Cytol       Date:  1982 Jul-Aug       Impact factor: 2.319

7.  Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions.

Authors:  A A Epenetos; G Canti; J Taylor-Papadimitriou; M Curling; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

8.  Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium.

Authors:  R J Marshall; A Herbert; S G Braye; D B Jones
Journal:  J Clin Pathol       Date:  1984-11       Impact factor: 3.411

9.  Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining.

Authors:  W S Kwee; R W Veldhuizen; R P Golding; H Mullink; J Stam; R Donner; M E Boon
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

10.  Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies.

Authors:  A K Ghosh; K C Gatter; M S Dunnill; D Y Mason
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

View more
  1 in total

1.  ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.

Authors:  C J O'Hara; J M Corson; G S Pinkus; R A Stahel
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.